Elekta Ab Class B · OMXSTO:EKTA_B
Elekta Ab Class B — Merger or Acquisition (September 2011)
11 slides from Elekta Ab Class B's merger presentation, Sep 15, 2011
Slide 1: Closing of Nucletron acquisition
Closing of Nucletron acquisition Building a stronger position in the cancer care market September 15, 2011
Slide 2: Important step in Elekta's growth strategy
Important step in Elekta’s growth strategy • Nucletron is the world leader in Brachytherapy and an important step in Elekta’s growth strategy: – Strengthened market positions and more comprehensive customer offering – Combined customer base of 6,000 customers serving close to one million patients ev
Slide 3: Company snapshot
Company snapshot Company overview Financial profile • Headquartered in Veenendaal, Netherlands; • Solid financial performance Founded in 1975; ~500 employees – 2010 sales growth of 14% • Highly successful radiotherapy company – 2010 EBITDA growth of 29% specialised in Brachytherapy treatment solutio
Slide 4: State of the art product portfolio
State of the art product portfolio Brachytherapy • Brachytherapy involves precisely placing a radiation Afterloaders Applicators Software source internally, either into or immediately next to the cancerous tumour • Able to reach sites not typically accessible via external beam • Prevalent in gynaeco
Slide 5: Brachytherapy's important role in cancer care
Brachytherapy’s important role in cancer care Radiation therapy (RT) is an integral part of cancer care Brachytherapy accounts for ~5-10% (1) of the RT market Applications of Brachytherapy(2) Medical Oncology Radiation Therapy 15% 12% 47% 3-5x cost of radiation therapy 26% Surgery 2x cost of Gynae
Slide 6: Elekta will have better access to oncology care in fast-growing emerging markets
Elekta will have better access to oncology care in fast-growing emerging markets #1 #1 #2 (1) Market position (2) Nucletron: Direct Sales Distributor Brachytherapy is an important treatment option in emerging markets due to: • Lower maintenance and installation costs • Shorter treatment times •
Slide 7: Financial considerations
Financial considerations Human Care Makes ih the Future Possible () E L E KTA
Slide 8: Financial considerations
Financial considerations • Purchase price of EUR 365 M on a cash and debt free basis • Nucletron reported net sales in 2010 of EUR 128 M and EBITDA of EUR 26 M, representing a margin of 20% • Nucletron is expected to add approx. SEK 850 M to Elekta’s net sales and SEK 170 M to Elekta’s EBIT in fisca
Slide 9: Financial considerations
Financial considerations • Transaction and restructuring costs of approx. SEK 170 M – Transaction costs of approx. SEK 40 M; of which SEK 30 M to be charged in Q2 2011/12, SEK 10 M already charged in Q1 – SEK 130 M in restructuring costs, incurred during second half of fiscal year 2011/12 and during
Slide 10: Important step in Elekta's growth strategy
Important step in Elekta’s growth strategy • Nucletron is the world leader in Brachytherapy and an important step in Elekta’s growth strategy • Combined customer base of 6,000 customers serving close to one million patients with our cancer care solutions every year • Nucletron has a strong financial
Slide 11: Human Care Makes the Future Possible
Human Care Makes the Future Possible a E L E KTA I Nucletron Improving patient care